| rotigotine XR microspheres (LY03003) / Luye Group |
NCT04627155: A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 |
|
|
| Completed | 1 | 20 | NA | LY03003 | Luye Pharma Group Ltd. | Parkinson Disease | 05/13 | 05/13 | | |
NCT04044547: A Study of LY03003 in Patients With Early-stage Parkinson's Disease |
|
|
| Completed | 1 | 60 | NA | Rotigotine, extended-release microspheres, Placebo, extended-release microspheres | Luye Pharma Group Ltd., Beijing Bozhiyin T&S Co., Ltd. | Parkinson Disease | 02/14 | 06/15 | | |
03003MAD, NCT02055274: Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease |
|
|
| Completed | 1 | 39 | US | LY03003, Neupro | Luye Pharma Group Ltd. | Parkinson's Disease | 08/15 | 08/15 | | |
NCT03589066: Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease |
|
|
| Completed | 1 | 24 | US | LY03003, rotigotine | Luye Pharma Group Ltd. | Parkinson Disease | 10/18 | 10/18 | | |
NCT03733561: A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro |
|
|
| Completed | 1 | 40 | US | LY03003, Neupro 4Mg/24Hr Transdermal Patch | Luye Pharma Group Ltd. | Parkinson Disease | 12/18 | 12/18 | | |
NCT04629404: A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients |
|
|
| Completed | 1 | 32 | RoW | LY03003, Placebo | Luye Pharma Group Ltd. | Parkinson Disease | 03/19 | 03/19 | | |
NCT04045678: A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease |
|
|
| Completed | 1 | 30 | RoW | LY03003 ( Rotigotine, extended-release microspheres), Placebo, extended-release microspheres | Luye Pharma Group Ltd., Beijing Bozhiyin T&S Co., Ltd. | Parkinson Disease | 04/19 | 06/19 | | |
NCT04384666: A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers |
|
|
| Completed | 1 | 56 | US | LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch | Luye Pharma Group Ltd. | Parkinson Disease | 08/20 | 08/20 | | |
NCT04630860: A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD |
|
|
| Completed | 1 | 30 | RoW | LY03003 | Luye Pharma Group Ltd. | Parkinson Disease | 05/21 | 01/22 | | |
